PharmaEssentia Corp (藥華醫藥) shares have jumped 80.56 percent since the company obtained a US polycythemia vera (PV) drug license for its new interferon drug Besremi (ropeginterferon alfa-2b-njft) on Nov. 12.
Shares on Friday closed at NT$195 in Taipei trading, up from the stock’s closing price of NT$108 on Nov. 12.
PV is a rare, chronic and life-threatening blood cancer linked to a stem cell mutation in the bone marrow that results in an overproduction of blood cells and places sufferers at risk of having a blood clot, stroke or heart attack.
Photo: CNA
PharmaEssentia is preparing to make Besremi available in the US in the coming weeks, which is expected to contribute sales and earnings to the company going forward, Yuanta Securities Investment Consulting Co (元大投顧) said in a note on Thursday.
“Besremi is the first first-line PV drug approved by the US Food and Drug Administration (FDA), and can be used on any PV patients regardless of prior treatments,” Yuanta said. “We see a positive outlook for Besremi sales in the US going forward, despite that the new drug’s pricing of US$180,000 per person per year is higher than previously expected.”
In the US, the number of people with PV who are administered Besremi is projected to rise by 800 per year after the drug is launched there, with US sales of Besremi likely to reach US$100 million next year and increase by US$100 million every year after that, Yuanta said.
“Besremi might also cut into the sales of other first and second-line PV drugs, with an estimated revenue of US$900 million in the US in 2030,” it said.
PharmaEssentia last week reported revenue of NT$42.4 million (US$1.52 million) for last month, up 53.2 percent month-on-month and 10.65 percent year-on-year. Cumulative revenue in the first 10 months of the year totaled NT$318.9 million, an increase of 5.13 percent from last year.
With the new drug, the company has high hopes that its balance sheet will improve after posting losses per share of NT$4.74 in the first three quarters of the year, a company regulator filing showed.
In the US, Besremi has been designated an orphan drug for PV, and with the FDA’s approval, PharmaEssentia would have seven years of orphan drug exclusivity (ODE) in the US market.
Aside from the US, Besremi has received approval in Taiwan, the EU and South Korea for PV treatment, the company said.
The company has also recruited 87 people, more than half of the number it plans to recruit, for global clinical phase 3 trials of Besremi to treat essential thrombocythemia, it said.
PharmaEssentia expects to recruit all 160 participants needed for the trials by the second quarter of next year and to complete the trials in the middle of 2023, the company added.
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
RECORD-BREAKING: TSMC’s net profit last quarter beat market expectations by expanding 8.9% and it was the best first-quarter profit in the chipmaker’s history Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), which counts Nvidia Corp as a key customer, yesterday said that artificial intelligence (AI) server chip revenue is set to more than double this year from last year amid rising demand. The chipmaker expects the growth momentum to continue in the next five years with an annual compound growth rate of 50 percent, TSMC chief executive officer C.C. Wei (魏哲家) told investors yesterday. By 2028, AI chips’ contribution to revenue would climb to about 20 percent from a percentage in the low teens, Wei said. “Almost all the AI innovators are working with TSMC to address the
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”